

Reference number(s)
1707-A

# SPECIALTY GUIDELINE MANAGEMENT

## OCREVUS (ocrelizumab)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

- A. Ocrevus is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- B. Ocrevus is indicated for the treatment of primary progressive MS, in adults.

All other indications are considered experimental/investigational and not medically necessary.

#### II. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a neurologist.

#### III. CRITERIA FOR INITIAL APPROVAL

##### **A. Relapsing Forms of Multiple Sclerosis**

Authorization of 12 months may be granted to members who have been diagnosed with a relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse).

##### **B. Clinically Isolated Syndrome**

Authorization of 12 months may be granted to members for the treatment of clinically isolated syndrome of multiple sclerosis.

##### **C. Primary Progressive Multiple Sclerosis**

Authorization of 12 months may be granted to members for the treatment of primary progressive multiple sclerosis.

#### IV. CONTINUATION OF THERAPY

For all indications: Authorization of 12 months may be granted for members who are experiencing disease stability or improvement while receiving Ocrevus.

#### V. OTHER

Reference number(s)
1707-A

- A. Members will not use Ocrevus concomitantly with other disease modifying multiple sclerosis agents (Note: Ampyra and Nuedexta are not disease modifying).
- B. Authorization may be granted for pediatric members less than 18 years of age when benefits outweigh risks.

**VI. REFERENCES**

1. Ocrevus [package insert]. South San Francisco, CA: Genentech, Inc.; March 2023.
2. Clinical Consult: CVS Caremark Clinical Program Review. Focus on Multiple Sclerosis Clinical Programs. June 22, 2017.